Cognition Therapeutics, Inc.
US ˙ NasdaqCM ˙ US19243B1026

SecurityCGTX / Cognition Therapeutics, Inc.
InstitutionSigma Planning Corp
Latest Disclosed Ownership337,765 shares
Latest Disclosed Value $ 256,533
Sigma Planning Corp reports 56.25% increase in ownership of CGTX / Cognition Therapeutics, Inc.

On May 4, 2026 - Sigma Planning Corp filed a 13F-HR form disclosing ownership of 337,765 shares of Cognition Therapeutics, Inc. (US:CGTX) valued at $256,533 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 30, 2026 disclosing 216,165 shares of Cognition Therapeutics, Inc.. This represents a change in shares of 56.25% during the quarter. The current value of the position is $459,360 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F COGNITION THERAPEUTICS COM 19243B102 337,765 121,600 56.25 257 -12.93 0.0071
2026-01-30 2025-12-31 13F COGNITION THERAPEUTICS COM 19243B102 216,165 89,075 70.09 295 71.93 0.0081
2025-11-10 2025-09-30 13F COGNITION THERAPEUTICS COM 19243B102 127,090 -20,900 -14.12 172 280.00 0.0049
2025-08-05 2025-06-30 13F COGNITION THERAPEUTICS COM 19243B102 147,990 -460,400 -75.68 46 -82.42 0.0014
2025-05-02 2025-03-31 13F COGNITION THERAPEUTICS COM 19243B102 608,390 -6,100 -0.99 256 -40.47 0.0082
2025-02-03 2024-12-31 13F COGNITION THERAPEUTICS COM 19243B102 614,490 417,300 211.62 431 367.39 0.0135
2024-11-04 2024-09-30 13F COGNITION THERAPEUTICS COM 19243B102 197,190 25,050 14.55 92 -67.72 0.0028
2024-08-06 2024-06-30 13F COGNITION THERAPEUTICS COM 19243B102 172,140 12,700 7.97 286 -1.72 0.0091
2024-05-02 2024-03-31 13F COGNITION THERAPEUTICS COM 19243B102 159,440 130,890 458.46 290 457.69 0.0091
2024-02-01 2023-12-31 13F COGNITION THERAPEUTICS COM 19243B102 28,550 28,550 53 0.0041
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.